Trial Profile
A randomised Phase II study of carboplatin with or without the addition of the ETAR inhibitor ZD4054 as treatment for patients with metastatic breast cancer.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Zibotentan (Primary) ; Carboplatin
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms PLANET
- 18 May 2018 Status has been changed to withdrawn prior to enrolment.
- 18 May 2018 Planned End Date changed from 31 May 2013 to 16 Aug 2011.
- 18 May 2018 Planned primary completion date changed from 1 Aug 2012 to 16 Aug 2011.